Faes Farma, S.A. (0K9H.IL)
- Previous Close
4.1225 - Open
0.0000 - Bid 4.0250 x --
- Ask --
- Day's Range
0.0000 - 0.0000 - 52 Week Range
0.0000 - 4.1450 - Volume
43,696 - Avg. Volume
16,859 - Market Cap (intraday)
1.397B - Beta (5Y Monthly) 0.55
- PE Ratio (TTM)
14.74 - EPS (TTM)
0.2800 - Earnings Date Apr 30, 2025
- Forward Dividend & Yield 0.07 (2.38%)
- Ex-Dividend Date Apr 12, 2023
- 1y Target Est
--
Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and markets pharmaceutical products and raw materials in Spain and internationally. The company's products include prescription drugs, generic drugs, over-the-counter (OTC) drugs, food supplements, baby foods, and other health products. It offers Actimag, a magnesium pidolate; Bilaxten, an anti-allergic; Bronquidiazina CR, an anti-infective; Claversal for ulcerative colitis and Crohn's disease; Dezacor, a corticoid; Dolotren, an anti-inflammatory; Dolotren Gel; Dynamogen, an anti-anorexic; Ferroprotina, an anti-anaemic; Hidroferol; Lipofen; Positon for dermatitis; strength builder products, such as Potenciator and Surmenalit; Pruina, a laxative; Robaxisal Compuesto, a muscle relaxant and analgesic; Trausan, a citicoline; Venosmil, a venous vasoprotector; Venosmil Gel; and Yendol, an anti-flu. The company also provides Bilastine, an antihistamine molecule for the treatment of allergic rhino conjunctivitis and urticarial; Calcifediol for bone metabolism; Deflazacort to treat osteoarticular disease; Hidrosmin for venous insufficiency; and Mesalazine to treat digestion problems. In addition, it manufactures and sells animal nutrition and health products. It also exports its products. Faes Farma, S.A. was incorporated in 1933 and is headquartered in Leioa, Spain.
faesfarma.com1,764
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 0K9H.IL
View MorePerformance Overview: 0K9H.IL
Trailing total returns as of 4/24/2025, which may include dividends or other distributions. Benchmark is IBEX 35... (^IBEX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0K9H.IL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0K9H.IL
View MoreValuation Measures
Market Cap
1.28B
Enterprise Value
1.23B
Trailing P/E
11.58
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.61
Price/Book (mrq)
1.77
Enterprise Value/Revenue
2.50
Enterprise Value/EBITDA
9.61
Financial Highlights
Profitability and Income Statement
Profit Margin
19.13%
Return on Assets (ttm)
8.90%
Return on Equity (ttm)
14.58%
Revenue (ttm)
468.68M
Net Income Avi to Common (ttm)
89.64M
Diluted EPS (ttm)
0.2800
Balance Sheet and Cash Flow
Total Cash (mrq)
46.52M
Total Debt/Equity (mrq)
2.34%
Levered Free Cash Flow (ttm)
-36.55M